BIOC - Biocept, Inc.
| Previous Close | 3.34 |
| Open | 3.29 |
| Bid | 2.98 x 1100 |
| Ask | 3.04 x 800 |
| Day's Range | 2.94 - 3.29 |
| 52 Week Range | 2.86 - 40.50 |
| Volume | 190,653 |
| Avg. Volume | 517,965 |
| Market Cap | 6.708M |
| Beta | -0.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -15.44 |
| Earnings Date | Nov 7, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.50 |
- PR Newswire•5 hours ago
Biocept Announces Pricing of $2.5 Million Registered Direct Offering Priced at Market
SAN DIEGO, Sept. 21, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $2.5 million of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) in a registered direct offering and concurrent private placement at market. The combined purchase price for one share of common stock (or one pre-funded warrant to purchase common stock in lieu thereof) and each warrant will be priced at $3.285.
- PR Newswire•11 days ago
Biocept Names Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer
SAN DIEGO, Sept. 10, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the appointment of Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer. Mr. Hendrick brings to Biocept over 25 years of sales and commercial leadership experience in the healthcare industry, with recent senior level commercial and operational positions in the clinical diagnostics segment. "Edwin's outstanding experience developing successful commercial organizations in early-stage companies is a natural fit for Biocept, as we aim to continue to build our market presence in the emerging liquid biopsy segment," said Michael Nall, President and Chief Executive Officer of Biocept.
- PR Newswire•15 days ago
Biocept's Target Selector Platform Featured in Two Poster Presentations at the IASLC 19th World Conference on Lung Cancer
SAN DIEGO, Sept. 6, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that two poster presentations featuring clinical data sets using its Target Selector™ liquid biopsy platform will be presented at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer. The conference is being held September 23-26, 2018 in Toronto at the Metro Toronto Convention Centre.
- PR Newswire•29 days ago
Highmark Health's VITAL Innovation Program testing benefits of Biocept's liquid biopsy platform for improving outcomes and lowering costs of treatment for patients with non-small cell lung cancer
Allegheny Health Network's Cancer Institute spearheading the evaluation PITTSBURGH and SAN DIEGO , Aug. 23, 2018 /PRNewswire/ -- Highmark Health announced today that through its VITAL Innovation Program, ...
- Benzinga•last month
The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 14) DexCom, Inc. (NASDAQ: DXCM ) Masimo Corporation (NASDAQ: MASI ...
- PR Newswire•last month
Biocept Reports Second Quarter 2018 Financial Results
Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , Aug. 14, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to ...
- PR Newswire•last month
Biocept to Release Second Quarter 2018 Financial Results and Host Investor Conference Call on August 14, 2018
SAN DIEGO , Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable ...
- PR Newswire•last month
Biocept Announces $11.6 Million in Expected Gross Proceeds from Recently Expired Rights Offering
SAN DIEGO, Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announced today that the Company's previously announced rights offering (the "Rights Offering") expired on Wednesday, August 8, 2018 and these rights are no longer exercisable. The Company accepted all valid subscriptions that were presented and estimates that the Rights Offering will result in approximately $11.6 million in gross proceeds.
- PR Newswire•2 months ago
Biocept Announces Agreement with Managed Care Plan to Study the Benefits of Implementing Liquid Biopsy to Improve Patient Outcomes and Lower Healthcare Costs
SAN DIEGO, Aug. 6, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered into an agreement with a large integrated healthcare delivery network to evaluate the clinical utility and cost effectiveness of using Biocept's Target Selector™ testing in patients diagnosed with non-small cell lung cancer (NSCLC). As part of the agreement, the Company's liquid biopsy testing will be used to profile patients who have been diagnosed with NSCLC and/or have progressed on EGFR targeted therapy.
- PR Newswire•2 months ago
Biocept Awarded Patent in Canada for its Target Selector CTC Platform
Further expands global patent estate for capturing and detecting biological targets of interest including rare cells such as circulating tumor cells (CTCs) SAN DIEGO , Aug. 2, 2018 /PRNewswire/ -- Biocept, ...
- PR Newswire•2 months ago
European Patent Granted for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Platform
The patent provides intellectual property protection in seven European countries and is core to Biocept's Target Selector™ assays for ctDNA analysis using real-time PCR, Sanger sequencing and next-generation sequencing (NGS).
- PR Newswire•2 months ago
Biocept and UC San Diego Moores Cancer Center Announce Collaboration to Study Feasibility of Liquid Biopsy to Predict Disease Recurrence in Solid Tumors and Response to Therapy
SAN DIEGO, July 23, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will work with Moores Cancer Center at UC San Diego Health to conduct two clinical studies in patients with a variety of solid tumors.
- PR Newswire•2 months ago
Biocept Reminds Investors of Today's Deadline to be a Shareholder of Record
SAN DIEGO, July 19, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC) ("Biocept"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today issued a reminder to shareholders that the record date of its proposed rights offering is Monday, July 23, 2018. To be a shareholder of record on the record date, ownership of Biocept stock must occur by market close on Thursday, July 19, 2018 to account for settlement.
- Zacks•2 months ago
Biocept, Inc. (BIOC) Soars: Stock Adds 9.8% in Session
Biocept (BIOC) was a big mover last session, as the company saw its shares rise more than 9% on Friday amid huge volumes.
- ACCESSWIRE•2 months ago
Today's Research Reports on Stocks to Watch: Biocept and Johnson and Johnson
NEW YORK, NY / ACCESSWIRE / July 16, 2018 / Johnson & Johnson shares saw a drop on Friday as traders reacted to last week’s court decision that the company owes $4.69 billion to 22 women over its talc-based products allegedly causing them cancer. The company is vehement on appealing the court order. Biocept shares were skyrocketing on an announcement that it has entered into an agreement with Alliance Global FZ to market and distribute liquid biopsy testing in the Middle East, Southeast Asia, and the Africa region.
- Motley Fool•2 months ago
Why RH, Biocept, and Lowe's Jumped Today
One of these companies said investors shouldn't worry about proposed China tariffs.
Market Realist•2 months agoWhy Biocept’s Stock Price Is Soaring Today
Today, Biocept (BIOC) is trading at a stock price of $10.72, which represents ~63.66% growth from yesterday’s close of $6.55.
- InvestorPlace•2 months ago
BIOC: What’s Going on With Biocept Stock?
Biocept stock (NASDAQ:BIOC) was skyrocketing on Friday as the company announced a biopsy testing partnership with Alliance Global FZ. Biocept’s bread and butter is the development and administration of liquid biopsy tests that allow physicians to amass clinically actionable information to help improve the outcomes of patients who have been diagnosed with cancer. The company has inked a deal with Alliance Global to market and distribute Biocept’s Target Selector liquid biopsy tests.
- Motley Fool•2 months ago
Why Biocept, Inc. Is Rebounding Big-Time Today
The molecular diagnostics company inked a new distribution deal that helped investors forget yesterday's bad news.
- Benzinga•2 months ago
Biocept Rallies On Marketing Agreement For Proprietary Liquid Biopsy Tests
Biocept Inc (NASDAQ: BIOC ) shares were ripping higher Friday following the announcement of a provider agreement with Alliance Global. The stock was rallying 58.32 percent to $10.31 at the time of publication. ...
- PR Newswire•2 months ago
Biocept Enters into Agreement with Alliance Global FZ to Market and Distribute Liquid Biopsy Testing in the Middle East, Southeast Asia, and Africa Region
SAN DIEGO, July 13, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces a provider agreement with Alliance Global FZ, LLC to market and distribute Biocept's Target Selector™ liquid biopsy tests in the United Arab Emirates and select countries in the Middle East, North & Sub-Saharan Africa, and Southeast Asia (MEAA) region. All diagnostic testing services under this agreement will be performed in Biocept's San Diego-based CLIA-certified laboratory with Alliance Global having responsibility for sales, marketing, distribution, and reimbursement of the Company's liquid biopsy platform.
- Motley Fool•2 months ago
Why Biocept, Inc. Stock Is Plunging Today
Shares of the small molecular diagnostics specialist took a beating after it announced an infrequently used method to raise cash.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Biocept and Myriad Genetics
NEW YORK, NY / ACCESSWIRE / July 12, 2018 / U.S. equities saw losses on Wednesday, breaking a winning streak of four consecutive days, as trade tensions grew following the White House's announcement of ...
- PR Newswire•2 months ago
Biocept Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering
SAN DIEGO , July 11, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) ("Biocept"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable ...
- PR Newswire•3 months ago
Biocept Highlights Recent Progress and Outlines Near-Term Strategic Priorities in CEO Letter to Stockholders
In the past several months we have undertaken a range of initiatives that capitalize on our proprietary technology platform and support our portfolio of commercial tests that provide clinically actionable information from a simple blood sample.
